Src Kinase Inhibitor I

Base Information

• Chemical Name: Src Kinase Inhibitor I
• CAS No.: 179248-59-0
• Molecular Formula: C22H19N3O3
• Molecular Weight: 373.40500
• European Community (EC) Number: 686-974-3
• DSSTox Substance ID: DTXSID50363056
• Nikkaji Number: J1.446.049G
• Wikidata: Q27088870
• Pharos Ligand ID: AJFLRXB8SLD8
• ChEMBL ID: CHEMBL97771
• Mol file: 179248-59-0.mol

Synonyms:Src Kinase Inhibitor I;179248-59-0;Src Inhibitor 1;Src I1;6,7-dimethoxy-N-(4-phenoxyphenyl)quinazolin-4-amine;Src Inhibitor-1;4-Quinazolinamine, 6,7-dimethoxy-N-(4-phenoxyphenyl)-;Src-l1;Src I 1;6,7-dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine;CHEMBL97771;4-(4'-PHENOXYANILINO)-6,7-DIMETHOXYQUINAZOLINE;Src Kinase Inhibitor 1;CHEBI:78332;6,7-Dimethoxy-N-(4-phenoxyphenyl)-;Src-I1;SKI-1;SRC-kinase-inhibitor-I;Bionet1_003516;D0U2QT;Oprea1_231056;GTPL6042;SCHEMBL1387206;HMS578L18;DTXSID50363056;HMS3229K19;HMS3414E03;HMS3678E03;BCP24909;EX-A1230;BDBM50095227;HSCI1_000234;MFCD01815300;s6567;AKOS002350963;Src Inhibitor-1, >=98% (HPLC);CCG-206789;CS-6178;KIN001-030;NCGC00370851-01;HY-101053;FT-0667227;Src Kinase Inhibitor I - CAS 179248-59-0;11N-067;(4'-oxyphenyl-phenylamino)-6,7-dimethoxyquinazoline;J-011437;BRD-K50495309-001-01-2;N-(4-Phenoxyphenyl)-6,7-dimethoxy-4-quinazolinamine;Q27088870;(6,7-Dimethoxy-quinazolin-4-yl)-(4-phenoxy-phenyl)-amine

Chemical Property of Src Kinase Inhibitor I

Chemical Property:

• PSA: 65.50000
• LogP: 5.25590
• Storage Temp.: Desiccate at RT
• Solubility.: DMSO: >10mg/mL
• XLogP3: 4.9
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 6
• Exact Mass: 373.14264148
• Heavy Atom Count: 28
• Complexity: 466

Purity/Quality:

99% ^*data from raw suppliers

Src I1 ^*data from reagent suppliers

Safty Information:

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)OC4=CC=CC=C4)OC
• Description: Src-I1 (179248-59-0) is a potent and competitive dual site (ATP- and peptide-binding) Src kinase inhibitor (IC50‘s = 44 nM for Src and 88 nM for Lck). Src-I1 also inhibits VEGFR2 (IC50 = 320 nM).
• Uses: Src Kinase inhibitor 1 lung cancers with EGF receptor abnormalities and is a potential candidate for mol.-targeted therapy Src Inhibitor-1 may be used in Src kinase-mediated cell signaling studies.